In GBM or other treatment-resistant primary cancers, CAR-T cells targeting CD133-positive tumor-initiating cells, a marker of radioresistance in multiple aggressive cancers, demonstrated superior efficacy (88). This evidence concerns the gene PROM1 and cancer.